# Silencing Inflammatory Activity by Injecting Nanocort in Patients at Risk for Atherosclerotic Disease

> **NCT01601106** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)** · enrollment: 30 (estimated)

## Conditions studied

- Atherosclerosis
- Inflammation

## Interventions

- **DRUG:** liposomal prednisolone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01601106
- **Lead sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-09
- **Primary completion:** 2013-05
- **Final completion:** —
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2012-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01601106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01601106, "Silencing Inflammatory Activity by Injecting Nanocort in Patients at Risk for Atherosclerotic Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01601106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*